Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer. [PDF]
Chigutsa E, Chapman SC, Turner PK.
europepmc +1 more source
EC<sub>50</sub> and EC<sub>95</sub> of Epidural Ropivacaine for Intraoperative Analgesia During High-Intensity Focused Ultrasound for Adenomyosis: A Prospective Double-Blind Up-and-Down Concentration-Finding Study. [PDF]
Yang S, Zhang Y, Yang F, Luo L.
europepmc +1 more source
Controlled Maxillofacial Administration of Levodopa in a Patient With Parkinson's Disease: A First-in-Human 24-Hour Follow-Up Study. [PDF]
Thirunavukarasu SC +10 more
europepmc +1 more source
Effectiveness of low-dose perampanel in focal epilepsy patients aged twelve or older in Southern China: an observational study. [PDF]
Lu X +6 more
europepmc +1 more source
Clinical Pharmacology and Translational Science Considerations in the Development of Dual-Payload Antibody Drug Conjugates. [PDF]
Ravenstijn P +5 more
europepmc +1 more source
An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response. [PDF]
De Marco D +6 more
europepmc +1 more source
Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis. [PDF]
Furukawa Y +9 more
europepmc +1 more source
Antiseizure Effects of Cannabidiol in Combination With Cannabigerol in the Maximal Electroshock Seizure Model. [PDF]
Zhou HZ +3 more
europepmc +1 more source
Pharmacokinetics and Exploratory Exposure-Response Analysis of Chikusetsusaponin IVa in Myocardial Ischemia/Reperfusion-Injured Rats. [PDF]
Shuai X +7 more
europepmc +1 more source
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach. [PDF]
Overgaard RV +6 more
europepmc +1 more source

